BioCentury
ARTICLE | Clinical News

Anti-CD40L Fab: Phase Ib started

November 11, 2013 8:00 AM UTC

UCB disclosed in its earnings for the 9 months ended Sept. 30 that it began a Phase Ib trial to evaluate CDP7657 in patients with SLE. Biogen Idec and UCB are co-developing CDP7657 to treat SLE. ...